| Eribulin studied in …STUDIED_INderived167 of 167show fewer |
|---|
| → studied in | NCT03734029Phase 3 · completed Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07007559Phase 2 · recruiting ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07173751Phase 3 · recruiting ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07824869Phase 2 · not yet recruiting A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04579224Phase 3 · active not recruiting Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer · 167 trials list this drug (45 active) | — | — | Urothelial Carcinoma,Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07811232Phase 1/Phase 2 · not yet recruiting A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Soft Tissue Sarcoma,Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00365157Phase 1/Phase 2 · active not recruiting Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction · 167 trials list this drug (45 active) | — | — | Transitional Cell Carcinoma,Urothelial Carcinoma,Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05570253Phase 2 · recruiting A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03331250Phase 2 · completed Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) · 167 trials list this drug (45 active) | — | — | Epithelioid Hemangioendothelioma,Angiosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05104866Phase 3 · active not recruiting A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06263231Phase 3 · recruiting A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) · 167 trials list this drug (45 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03237780Phase 2 · active not recruiting Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer · 167 trials list this drug (45 active) | — | — | Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm,Malignant Ureter Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04345913Phase 1/Phase 2 · active not recruiting Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06343948Phase 3 · active not recruiting A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06382142Phase 3 · active not recruiting A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05458674Phase 2 · active not recruiting Tucatinib+Trastuzumab+Eribulin in HER2+ MBC · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02623972Phase 2 · active not recruiting A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06449222Phase 2 · active not recruiting Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04986579Phase 2 · recruiting Scalp Cooling in MBC · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03202316Phase 2 · active not recruiting Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06957431Phase 1 · recruiting Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma · 167 trials list this drug (45 active) | — | — | Sarcoma,Liposarcoma,Leiomyosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07461454Phase 3 · recruiting YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06006273Phase 1 · recruiting A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors · 167 trials list this drug (45 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05374512Phase 3 · active not recruiting A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06081959Phase 3 · recruiting Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06279364Phase 3 · recruiting A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07494448Phase 1/Phase 2 · not yet recruiting Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03361436Phase 1 · active not recruiting Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery · 167 trials list this drug (45 active) | — | — | Malignant Abdominal Neoplasm,Malignant Solid Neoplasm,Liposarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05810870Phase 2 · active not recruiting PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06435429Phase 3 · recruiting A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer · 167 trials list this drug (45 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04639986Phase 3 · active not recruiting Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06519370Phase 3 · active not recruiting FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03526679Phase 1/Phase 2 · completed Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma · 167 trials list this drug (45 active) | — | — | Malignant Neoplasm,Liposarcoma,Soft Tissue Sarcoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07255612Phase 2 · not yet recruiting Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05530057Phase 2 · recruiting Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06328738Phase 1 · active not recruiting ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer · 167 trials list this drug (45 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm,HER2-Positive Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01676818Phase 2 · completed Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer · 167 trials list this drug (45 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03264547Phase 3 · completed A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06942234Phase 1/Phase 2 · recruiting Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06079983Phase 3 · recruiting JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02514681Phase 3 · completed A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05063786Phase 3 · active not recruiting Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03899805Phase 2 · completed A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas · 167 trials list this drug (45 active) | — | — | Sarcoma,Liposarcoma,Leiomyosarcoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06255392Phase 3 · recruiting Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06590558Phase 1 · withdrawn Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Invasive Breast Carcinoma,HER2-Negative Breast Carcinoma,Hormone Receptor-Positive Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05041101Phase 1/Phase 2 · terminated Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02061085Phase 2 · completed Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03222856Phase 2 · completed Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02419495Phase 1 · terminated Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies · 167 trials list this drug (45 active) | — | — | Malignant Solid Neoplasm,Melanoma,Malignant Lung Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02299999Phase 2 · active not recruiting SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06731153Phase 2 · not yet recruiting JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06143553Phase 3 · unknown Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05824975Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) · 167 trials list this drug (45 active) | — | — | Solid Neoplasm,Cutaneous Melanoma,Soft Tissue Sarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06102824Phase 2 · recruiting Organoid-based Functional Precision Therapy for Advanced Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01827787Phase 2 · completed Eribulin in HER2 Negative Metastatic BrCa · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03901339Phase 3 · completed Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03840772Phase 2 · completed Eribulin in Advanced Solitary Fibrous Tumor · 167 trials list this drug (45 active) | — | — | Solitary Fibrous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02681523Phase 2 · terminated ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer. · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02037529Phase 3 · suspended Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Breast Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06539559Phase 2 · unknown Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06387628Phase 2 · recruiting LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464174Phase 2 · completed Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03393741terminated Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02035813Phase 2 · completed DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02344472Phase 3 · unknown Detect V / CHEVENDO (Chemo vs. Endo) · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02640508Phase 2 · completed Eribulin and Lenvatinib in Advanced Solid Tumors · 167 trials list this drug (45 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02338037early Phase 1 · completed Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors · 167 trials list this drug (45 active) | — | — | Brain Neoplasm,Primary Brain Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06308939Phase 2 · unknown Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06202261Phase 1/Phase 2 · recruiting A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03051659Phase 2 · completed A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06268652Phase 3 · recruiting Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238831early Phase 1 · withdrawn SMMART Adaptive Clinical Treatment (ACT) Trial · 167 trials list this drug (45 active) | — | — | Malignant Solid Neoplasm,Sarcoma,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06202313Phase 2 · not yet recruiting Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03786094Phase 3 · terminated Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01463891completed Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S) · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00879086Phase 2 · completed A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01126736Phase 1/Phase 2 · completed Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer · 167 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01268150Phase 2 · completed A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01269346Phase 2 · completed Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01439282Phase 2 · completed Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01454934Phase 3 · completed A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer · 167 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05833919Phase 2 · unknown Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05033769Phase 4 · unknown Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02915744Phase 3 · completed A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04303741Phase 2 · unknown A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04826016Phase 1/Phase 2 · withdrawn POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05206656Phase 2 · completed Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01795586Phase 1 · completed A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03579472Phase 1 · terminated M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03441360Phase 2 · completed Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) · 167 trials list this drug (45 active) | — | — | Ewing Sarcoma,Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05546255Phase 2 · unknown Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03027245completed Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02120469Phase 1 · completed Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03502681Phase 1 · terminated A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03245450Phase 1/Phase 2 · completed Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors · 167 trials list this drug (45 active) | — | — | Sarcoma,Ewing Sarcoma,Soft Tissue Sarcoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02574455Phase 3 · completed Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05402722Phase 2 · unknown Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02513472Phase 1/Phase 2 · completed Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04745975Phase 2 · unknown Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02824575Phase 1 · terminated Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02596503Phase 1 · completed A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors · 167 trials list this drug (45 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02555657Phase 3 · completed Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01705691Phase 2 · completed Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02404506Phase 2 · terminated Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01593020Phase 2 · completed Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03795012Phase 2 · terminated Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02551263completed Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04913571Phase 2 · unknown Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04624711Phase 2 · unknown Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02864030Phase 4 · completed PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01554371Phase 1/Phase 2 · completed Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01323530Phase 1/Phase 2 · completed A Confirmation Study of Eribulin in Combination With Capecitabine · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04683445unknown Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04681911Phase 2 · unknown Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04502680Phase 2 · unknown Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03430518Phase 1 · completed Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer · 167 trials list this drug (45 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02581839Phase 2 · completed Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01908101Phase 2 · completed Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01596751Phase 1/Phase 2 · completed Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02263495Phase 2 · completed Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02753595Phase 1/Phase 2 · terminated Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00337103Phase 3 · completed E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02097238Phase 2 · completed Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma · 167 trials list this drug (45 active) | — | — | Osteosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03637868Phase 2 · withdrawn Eribulin in Brain Metastases From HER2-negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03058406completed A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas · 167 trials list this drug (45 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02082626Phase 1 · terminated Study of Eribulin in Children With Cancer to Determine Safety · 167 trials list this drug (45 active) | — | — | Solid Neoplasm,Childhood Malignant Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02178241Phase 2 · completed Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery · 167 trials list this drug (45 active) | — | — | Bladder Urothelial Carcinoma,Malignant Ureter Neoplasm,Malignant Urethral Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03583944Phase 4 · completed A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01328249Phase 2 · completed Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01372579Phase 2 · unknown Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,Male Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03925233unknown Breast Cancer Treatment Based on Organ-like Culture · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02723877Phase 1/Phase 2 · completed PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03437083completed A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02171260Phase 1 · completed This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas · 167 trials list this drug (45 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01912963Phase 2 · terminated Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02481050Phase 2 · completed Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00410553Phase 1 · completed Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery · 167 trials list this drug (45 active) | — | — | Adult Solid Neoplasm,Ovarian Carcinoma,Malignant Uterine Corpus Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01613768Phase 2 · completed Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer · 167 trials list this drug (45 active) | — | — | Malignant Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01401959Phase 2 · completed Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412955Phase 2 · unknown A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00334893Phase 2 · completed Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer · 167 trials list this drug (45 active) | — | — | Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01669252Phase 2 · completed Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00383760Phase 2 · completed Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients · 167 trials list this drug (45 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03032614Phase 2 · withdrawn Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03245112unknown Halaven Patient Registry (Metastatic Breast Cancer, MBC) · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03002493Phase 1 · completed To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors · 167 trials list this drug (45 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01427933Phase 2 · completed A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01527487Phase 2 · completed Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01961544Phase 4 · completed Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01498588Phase 2 · terminated Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer · 167 trials list this drug (45 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02215876Phase 2 · withdrawn Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01458249Phase 2 · completed An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) · 167 trials list this drug (45 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01941407Phase 2 · completed First Line Metastatic Breast Cancer Treatment (ESMERALDA) · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02616848Phase 1 · unknown Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers · 167 trials list this drug (45 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01585870Phase 1 · completed Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination · 167 trials list this drug (45 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01388647Phase 1/Phase 2 · terminated Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00337129Phase 2 · completed S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer · 167 trials list this drug (45 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02396433Phase 1/Phase 2 · withdrawn Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01240421approved for marketing An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00400829Phase 2 · completed E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer · 167 trials list this drug (45 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00337077Phase 2 · completed Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy · 167 trials list this drug (45 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00415324Phase 1 · completed Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors · 167 trials list this drug (45 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01142661NA · completed Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00965523Phase 2 · completed Study of E7389 for Advanced or Metastatic Breast Cancer · 167 trials list this drug (45 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00047034Phase 1 · completed E7389 in Treating Patients With Advanced Solid Tumors · 167 trials list this drug (45 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01106248Phase 1 · completed QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors · 167 trials list this drug (45 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00908908Phase 1 · completed A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors · 167 trials list this drug (45 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |